Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Alkermes Rose 18% Last Month

By Jason Hawthorne - May 7, 2021 at 3:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An agreement with an activist investor capped a busy month.

What happened

Shares of Alkermes (ALKS 2.67%) climbed 17.8% in April, according to S&P Global Market Intelligence. Several positive developments boosted the maker of drugs for schizophrenia, as well as alcohol and opioid dependence. Alkermes announced a partnership to fight ovarian cancer, reported earnings that beat Wall Street estimates, and reached an agreement with an activist hedge fund that had been agitating for changes.

A man in the background struggling with addiction staring at bottles of opioids in the foreground.

Image source: Getty Images.

So what

Early in the month, the company announced it would advance the combination of nemvaleukin -- its drug that expands tumor-killing immune cells -- with Merck's Keytruda, to phase 3 trials. The combination has shown some anti-tumor activity against an especially difficult to treat form of ovarian cancer.

Near the end of the month, the company reported first-quarter results, with $251 million in revenue beating last year's top line and operating expenses coming in below 2019. That last bit about controlling costs seems to have been enough to facilitate a "constructive" dialogue with hedge fund Sarissa Capital. The activist, which owns about 5% of Alkermes, was given a seat on the company's board of directors as a result.

What now

As for the partnership with Merck, Alkermes is responsible for conducting the phase 3 study and anticipates beginning in the second half of 2021. In the meantime, the company recently initiated the phase 2 trial of nemvaleukin as a monotherapy to combat melanoma. 

After the agreement with Sarissa, its founder stated, "Alkermes has attractive and underappreciated assets that can drive meaningful value creation," so investors might expect management to trim assets that aren't currently contributing to the bottom line. With a history in mental illness and addiction, that could mean the company will look to sell the oncology assets it has been developing.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool recommends Alkermes. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
ALKS
$26.15 (2.67%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.